Wolfe Research analyst Andy Chen initiates coverage on Immunovant (NASDAQ:IMVT) with a Outperform rating and announces Price Target of $55.
Wolfe Research Initiates Coverage On Immunovant With Outperform Rating, Announces Price Target of $55
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.